ClinicalTrials.gg
CompletedNCT03816462ReNEWUpdated Jan 20, 2026

ReNEW Clinic Cohort Study

An observational study in Hypertension, Prehypertension and Obesity, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Johns Hopkins University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
Up to 22 Years
Sex
All
01

Study summary

This is an ongoing, prospective cohort study of children and young adults who are evaluated in the Reversing the Negative Effects of Weight on the Heart (ReNEW) Clinic at Johns Hopkins University.

Demographic and clinical data of patients who agree to participate are obtained via chart review and entered into a longitudinal clinic registry.

02

Conditions studied

  • Hypertension
  • Prehypertension
  • Obesity
  • Overweight
  • Left Ventricular Hypertrophy
  • Elevated Blood Pressure
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 200 is below the median of 350 across 1,163 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.

Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children between birth and 22 years of age with overweight or obesity referred for evaluation of elevated blood pressure in the ReNEW Clinic at Johns Hopkins University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and young adults with overweight or obesity referred for evaluation of elevated blood pressure in the ReNEW Clinic at Johns Hopkins University are eligible.

Exclusion criteria

Exclusion Criteria:

  • Children who are wards of the state or who are non-English speaking without an in-person interpreter accompanying them to the clinic visit.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Demographic and clinical data obtained via chart review

    This is a clinic based registry of cardiovascular disease risk data from participants to be collected over time.

    Time frame: 20 years

07

Study locations

1 site
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
08

References and documents

Publications

  • Wen W, Psoter KJ, Solomon BS, Urbina EM, Brady TM. Accuracy and Performance of Triage Blood Pressure Measurements in A Real-World Clinic Setting. J Pediatr. 2024 Jun;269:113962. doi: 10.1016/j.jpeds.2024.113962. Epub 2024 Feb 17. PubMed 38369238 ↗
  • Ducharme-Smith K, Brady TM, Vizthum D, Caulfield LE, Mueller NT, Rosenstock S, Garcia-Larsen V. Diet quality scores associated with improved cardiometabolic measures among African American adolescents. Pediatr Res. 2022 Sep;92(3):853-861. doi: 10.1038/s41390-021-01893-w. Epub 2021 Dec 16. PubMed 34916627 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Jan 2026, 132 months.

Of 345 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's 132 months is above that.

Counting every sponsor, half of 426 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2019
First posted
Jan 25, 2019
StartActual
Jan 2015
Primary completionActual
Jan 2026
CompletionActual
Jan 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03816462
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Jan 2015
Primary completion
Jan 2026
Completion
Jan 2026
Last update
Jan 20, 2026

Study contacts

Tammy M Brady
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion